VCYT:NSD-Veracyte Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 27.16

Change

0.00 (0.00)%

Market Cap

USD 2.51B

Volume

0.61M

Analyst Target

USD 38.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 37.95B
NTRA Natera Inc

N/A

USD 20.66B
ILMN Illumina Inc

N/A

USD 11.99B
ICLR ICON PLC

N/A

USD 11.79B
MEDP Medpace Holdings Inc

N/A

USD 8.65B
EXAS EXACT Sciences Corporation

N/A

USD 8.44B
GH Guardant Health Inc

N/A

USD 5.04B
RDNT RadNet Inc

N/A

USD 3.72B
SHC Sotera Health Co

N/A

USD 3.45B
WGS GeneDx Holdings Corp.

N/A

USD 1.95B

ETFs Containing VCYT

GN0M:XETRA Global X Genomics & Biote.. 5.00 % 0.00 %

N/A

USD 7.05M
GNOG:LSE Global X Genomics & Biote.. 4.94 % 0.00 %

N/A

USD 8.06M
GNOM:SW 4.94 % 0.00 %

N/A

N/A
DDOC:F Global X Telemedicine & D.. 4.08 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.02 % 0.00 %

N/A

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 2.00 % 0.00 %

N/A

USD 3.68M
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

N/A
EDOC:LSE Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 4.27M
EDOG:LSE Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.30M
WDNA WisdomTree BioRevolution .. 0.00 % 0.00 %

N/A

USD 1.98M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.41% 47% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.41% 47% F 22% F
Trailing 12 Months  
Capital Gain 30.58% 79% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.58% 79% B- 82% B
Trailing 5 Years  
Capital Gain 6.14% 81% B- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.14% 81% B- 43% F
Average Annual (5 Year Horizon)  
Capital Gain 2.08% 59% D- 50% F
Dividend Return 2.08% 57% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.28% 66% D+ 45% F
Risk Adjusted Return 5.29% 59% D- 42% F
Market Capitalization 2.51B 76% C+ 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.